Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 25 or more amino acid residues in defined sequence
Reexamination Certificate
2003-05-27
2008-08-26
Blanchard, David J. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
25 or more amino acid residues in defined sequence
C530S300000, C530S350000, C514S002600
Reexamination Certificate
active
07417113
ABSTRACT:
The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.
REFERENCES:
patent: 5738867 (1998-04-01), Spitler
patent: 5856136 (1999-01-01), Au-Young
patent: 6130043 (2000-10-01), Billing-Medel et al.
patent: 6207380 (2001-03-01), Billing-Medel et al.
patent: 6258939 (2001-07-01), Reiter et al.
patent: 6261789 (2001-07-01), Reiter et al.
patent: 6261791 (2001-07-01), Reiter et al.
patent: 6267960 (2001-07-01), Reiter et al.
patent: 6541212 (2003-04-01), Reiter et al.
patent: 6756036 (2004-06-01), Reiter et al.
patent: 6790939 (2004-09-01), Reiter et al.
patent: 6825326 (2004-11-01), Reiter et al.
patent: 6881822 (2005-04-01), Reiter et al.
patent: 6890749 (2005-05-01), Billing-Medel et al.
patent: 6960443 (2005-11-01), Reiter et al.
patent: 6979730 (2005-12-01), Reiter et al.
patent: 2002/0119157 (2002-08-01), Reiter et al.
patent: 2003/0113820 (2003-06-01), Reiter et al.
patent: 2005/0003465 (2005-01-01), Reiter et al.
patent: 2005/0026229 (2005-02-01), Reiter et al.
patent: 2005/0059099 (2005-03-01), Reiter et al.
patent: 2005/0152909 (2005-07-01), Reiter et al.
patent: 2005/0169930 (2005-08-01), Reiter et al.
patent: 2005/0282187 (2005-12-01), Billing-Medel et al.
patent: 2006/0269557 (2006-11-01), Sherman et al.
patent: WO 98/00540 (1998-01-01), None
patent: WO 98/51805 (1998-11-01), None
patent: WO 98/51824 (1998-11-01), None
Reiger et al. Glossary of Genetics and Cytogenetics, Classical and Molecular, 4th Ed., Springer-Verlay, Berlin, 1976, pp. 17-18.
Watson et al. Recombinant DNA, Scientific American Books, 1992.
Arlen, Myron et al., “Immunotherapy of Colon Cancer Using Chimeric mAb 31.1,”Critical Review in Immunology, 1998, 18:133-8. (Exhibit 2).
Arthur, Jill F. et al., “A Comparison of Gene Transfer Methods in Human Dendritic Cells,”Cancer Gene Therapy, 1997, 4:17-25. (Exhibit 3).
Ashley, David M. et al., “Bone Marrow-generated Dendritic Cells Pulsed with Tumor Extracts or Tumor RNA Induce Antitumor Immunity against Central Nervous System Tumors,”Journal of Experimental Medicine, Oct. 6, 1997, 186:1177-82. (Exhibit 4).
Bamezai, Anil and Kenneth L. Rock, “Overexpressed Ly-6A.2 Mediates Cell-Cell Adhesion by Binding a Ligand Expressed on Lymphoid Cells,”Proc Nat'l Acad Sci USA, May 1995, 92:4294-8. (Exhibit 5).
Brakenhoff, Ruud H. et al., “The Human E48 Antigen, Highly Homologous to the Murine Ly-6 Antigen ThB, is a GPI-anchored Molecule Apparently Involved in Keratinocyte Cell-Cell Adhesion,”Journal of Cell Biology, Jun. 1995, 129:1677-89. (Exhibit 6).
Braun, Benjamin S. et al., “Identification of Target Genes for the Ewing's Sarcoma EWS/FLI Fusion Protein by Representational Difference Analysis,”Molecular and Cell Biology, Aug. 1995, 15:4623-30. (Exhibit 7).
Cher, Michael L. et al., “Comparative Genomic Hybridization, Allelic Imbalance, and Fluorescence In Situ Hybridization on Chromosome 8 in Prostate Cancer,”Genes, Chromosomes&Cancer, 1994, 11:153-62. (Exhibit 8).
Cohen, Stanley N. et al., “Nonchromosomal Antibiotic Resistance in Bacteria: Genetic Transformation ofEscherichia coliby R-Factor DNA,”Proc. Nat'l Acad Sci USA, Aug. 1972, 69:2110-4. (Exhibit 9).
Cupp, Michael R. and Osterling, Joseph E., “Prostate-Specific Antigen, Digital Rectal Examination and Transrectal Ultrasonography: Their Roles in Diagnosing Early Prostate Cancer,”Mayo Clinic Proceedings, Mar. 1993, 68:297-306. (Exhibit 10).
Deleersnijder, Willy et al., “Isolation of Markers for Chondro-osteogenic Differentiation Using cDNA Library Subtraction,”Journal of Biological Chemistry, Aug. 9, 1996, 271:19475-82. (Exhibit 11).
Fields, Stanley and Ok-kyu Song, “A Novel Genetic System to Detect Protein-Protein Interactions,”Nature, Jul. 20, 1989, 340:245-6. (Exhibit 12).
Fong, Lawrence et al., “Induction of Tissue-Specific Autoimmune Prostatitis with Prostatic Acid Phosphatase Immunization Implications for Immunotherapy of Prostate Cancer,”Journal of Immunology, 1997, 159:3113-7. (Exhibit 13).
Foon, Kenneth A. et al., “Immune Response to the Carcinoembryonic Antigen in Patients Treated with an Anti-Idiotype Antibody Vaccine,”Journal of Clinical Investigation, Jul. 1995, 96:334-42. (Exhibit 14).
Fritz, Benjamin A. and Anson W. Lowe, “Polarized GP2 Secretion in MDCK Cells Via GPI Targeting and Apical Membrane-Restricted Proteolysis,”American Journal of Physiology, Jan. 1996, 270:G176-83. (Exhibit 15).
Funakoshi, Satoshi, et al., “Differential In Vitro and In Vivo Antitumor Effects Mediated by Anti-CD40 and AntiCD20 Monoclonal Antibodies Against Human B-Cell Lymphomas,”Journal of Immunotherapy, 1996, 19(2):93-101. (Exhibit 16).
Graham, F. L. and A. J. Van Der Eb, “A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA,”Virology, 1973, 52:456-67. (Exhibit 17).
Liu, He et al., “Constitutive and Antibody-induced Internalization of Prostate-specific Membrane Antigen,”Cancer Research, Sep. 15, 1998, 58:4055-60. (Exhibit 18).
Henderson, Robert A. et al., “Human Dendritic Cells Genetically Engineered to Express High Levels of the Human Epithelial Tumor Antigen Mucin (MUC-1),”Cancer Research, Aug. 15, 1996, 56:3763-70. (Exhibit 19).
Herlyn, Dorothee et al., “Anti-Idiotype Cancer Vaccines: Past and Future,”Cancer Immunology Immunotherapy, 1996, 43:65-76. (Exhibit 20).
Hodge, James W. et al., “A Recombinant Vaccinia Virus Expressing Human Prostate-Specific Antigen (PSA): Safety and Immunogenicity in a Non-Human Primate,”International Journal of Cancer, 1995, 63:231-7. (Exhibit 21).
Israeli, Ron S. et al., “Molecular Cloning of a Complementary DNA Encoding a Prostate-specific Membrane Antigen,”Cancer Research, Jan. 15, 1993, 53:227-30. (Exhibit 22).
Jenkins, Robert B. et al., “Detection of c-myc Oncogene Amplification and Chromosomal Anomalies in Metastic Prostatic Carcinoma by Fluorescence in Situ Hybridization,”Cancer Research, Feb. 1, 1997, 57:524-31. (Exhibit 23).
Kasprzyk, Philip G. et al., “Therapy of an Animal Model of Human Gastric Cancer Using a Combination of Anti-erbB-2 Monoclonal Antibodies,”Cancer Research, May 15, 1992, 52:2771-6. (Exhibit 24).
Katz, Ben-Zion et al., “An Association Between High Ly-6A/E Expression on Tumor Cells and a Highly Malignant Phenotype,”International Journal of Cancer, 1994, 59:684-91. (Exhibit 25).
Kieffer, Bruno et al., “Three-Dimensional Solution Structure of the Extracellular Region of the Complement Regulatory Protein CD59, a New Cell-Surface Protein Domain Related to Snake Venom Neurotoxins,”Biochemistry, 1994, 33:4471-82. (Exhibit 26).
Klein, Karen A. et al., “Progression of Metastatic Human Prostate Cancer to Androgen Independence in Immunodeficient SCID Mice,”Nature Medicine, Apr. 1997, 3:402-8. (Exhibit 27).
Lalani, El-Nasir et al., “Molecular and Cellular Biology of Prostate Cancer,”Cancer and Metastasis Reviews, 1997, 16:29-66. (Exhibit 28).
Lee, Cheryl T. and Joseph E. Oesterling, “Cancer of the Prostate: Diagnosis and Staging,”Urologic Oncology, 1997, W. B. Saunders Company, Philadelphia, 357-77. (Exhibit 29).
Magi-Galluzzi, C. et al., “Mitogen-Activated Protein Kinase Phosphatase 1 is Overexpressed in Prostate Cancers and is Inversely Related to Apoptosis,”Laboratory Investigation, Jan. 1997, 76:37-51. (Exhibit 30).
Mao Mao et al., “RIG-E, a Human Homolog of the Murine Ly-6 Family, is Induced by Retinoic Acid During the Differentiation of Acute Promyelocytic Leukemia Cell,”Proc Nat'l Acad Sci USA, Jun. 1996, 93:5910-4. (Exhibit 31).
Mount, Peter F. et al., “Chimeric (Mouse/Human) Anti-Colon
Raitano Arthur B.
Reiter Robert E.
Witte Owen N.
Agensys, Inc.
Blanchard David J.
The Regents of the University of California
Townsend and Townsend / and Crew LLP
LandOfFree
PSCA: prostate stem cell antigen and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with PSCA: prostate stem cell antigen and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and PSCA: prostate stem cell antigen and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4019801